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Abstract 
Background: Human T-cell lymphotropic virus type 1 (HTLV-1) is the etiological agent of HTLV associated myelopa-
thy/ Tropical Spastic Paraparesis (HAM/TSP) and Adult T cell leukemia/lymphoma (ATLL), in around 2–5% of the 
infected individuals. Host genetic background might play a role in disease progression. Several previous studies across 
many countries report HLA haplotype to be one such factor. Here, we sequenced HLA-A, -B and -C of 66 individuals 
by Sequence-Based Typing (SBT), and compared the frequency of different alleles among ATLL patients, HAM/TSP 
patients, asymptomatic carriers and non-infected individuals living in Argentina.
Results: The frequency of HLA-A, -B and -C alleles largely matched that of the general population in Argentina. We 
identified HLA-A*02, HLA-B*35 and HLA-C*07 as associated to protection from ATLL (p = 0.031), susceptibility to HAM/
TSP (p < 0.001) and susceptibility to ATLL (p = 0.017), respectively. We also found a strong correlation between high 
proviral load (PVL) and disease (p = 0.008), but were unable to identify any particular allele associated with high or low 
PVL.
Conclusions: We have found HLA-A*02, HLA-B*35 and HLA-C*07 to be associated to protection from ATLL (HLA-
A*02) and susceptibility to HAM/TSP (HLA-B*35) or to ATLL (HLA-C*07), respectively. Whereas HLA-A*02 protection 
from ATLL has already been extensively described in other regions of the world, this is the first report that links HLA-
B*35 and an increased susceptibility to HAM/TSP. As for HLA-C*07 it has previously been associated to susceptibility to 
HAM/TSP in other countries but in our population it has been linked to ATLL.
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Background
Human T-cell lymphotropic virus type 1 (HTLV-1) 
was the first human retrovirus to be discovered and is 
the etiological agent of Adult T Cell Leukemia/Lym-
phoma (ATLL), a progressive neurological disease called 
HTLV-1 Associated Myelopathy/Tropical Spastic Para-
paresis (HAM/TSP) [1, 2], Uveitis, a severity factor for 
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Northwestern region (Salta and Jujuy provinces) is con-
sidered endemic for HTLV-1 infection [4].
The vast majority of HTLV-1-infected individuals are 
asymptomatic and around 1–2% of them will develop 
ATLL and less than 5%, HAM/TSP. Although the risk 
factors causing different HTLV-1 associated diseases are 
not fully understood, their pathogenesis is thought to be 
in part due to proviral load (PVL) and/or the host genetic 
factors [5–7].
The target cells of HTLV-1 are  CD4+ T cells, and to a 
lesser extent CD8 + T cells, B cells, monocytes, mac-
rophages and dendritic cells [7]. The maintenance of 
HTLV-1 infection occurs mostly by clonal expansion 
of infected cells. In the case of ATLL, the expression of 
Tax protein in some of these clones with accumulated 
genomic abnormalities could help develop a pre-leu-
kemic state in some individuals. The malignantly trans-
formed HTLV-1 infected cells very often suppress Tax 
expression in favor of HTLV-1 basic leucine zipper fac-
tor (HBZ) expression, a negative regulator of Tax that is 
believed to aid immune evasion of the infected cells and 
further assist cancerous transformation [8]. On the other 
hand, the increased number of HTLV-1 infected T-cells 
may also cause imbalance of the immune system, result-
ing in immune dysfunction or inflammatory diseases like 
myelopathy and uveitis [9]. In this context, HAM/TSP 
pathogenesis is a hyperactive immune response induced 
by HTLV-1 infection that produces chronic inflammation 
in the central nervous system (CNS) with slowly progres-
sive evolution. It is characterized by the production of 
elevated levels of proinflammatory cytokines, including 
IFN-ɣ and TNF, and by HTLV-1-specific  CD8+ T cells in 
peripheral blood and spinal cord lesions [10–12].
Human Leukocyte Antigen (HLA) class I genes have 
been associated with susceptibility to disease in many 
human infections and it is among the host genetic fac-
tors that could be related to manifestation of ATLL and 
HAM/TSP [13, 14]. A unifying theory is that HLA alleles 
associated with ATLL show a limited recognition of 
HTLV-1 Tax peptide anchor motifs and epitopes capable 
of generating anti-HTLV-1 Tax  CD8+ T cells while for 
HAM/TSP they induce strong cytotoxic T-lymphocyte 
(CTL) responses against the viral oncoprotein Tax [15, 
16].
Specific HLA alleles have been linked to protection 
from developing these pathologies, whereas other HLA 
alleles have been correlated with an increased risk of 
developing them (Table  1). Some studies reported the 
HLA-A*02 allele to have a protective role both in ATLL 
and HAM/TSP disease in Jamaica, Brazil, Japan and Peru 
[16–21]. The same was the case for allele HLA-Cw*08 
in Japan and Iran [16, 20, 22]. HLA-A*26 and A*54 were 
associated with susceptibility to ATLL and HAM/TSP, 
respectively, in Japan, whereas A*36 was associated with 
susceptibility to ATLL in Jamaica [17, 23]. In contrast, 
HLA-B*5401 has been associated with an increased sus-
ceptibility to HAM/TSP in Japan and Iran [16, 24]. Allele 
C*07, on the other hand, has been associated to suscep-
tibility to disease in Brazil, only in patients who did not 
possess A*02 [25].
Another perspective suggests that greater HLA diver-
sity conveys selective advantage against disease because 
the immune response is elicited by a greater variety of 
antigens as described for human immunodeficiency 
virus (HIV) and acquired immunodeficiency syndrome 
(AIDS) [26]. Since each HLA allele exposes a different 
set of amino acids in their peptide cleft, they will each 
be able to present peptides with different specificities. 
This results in a heterogeneous capacity to activate T 
 CD8+ lymphocytes to target the infected cells. Carrying 
mismatched alleles for each HLA gene thus confers the 
ability to present a wider range of peptides, and to then 
be more likely to activate cytotoxic T cells to eliminate 
infected cells. It has been reported that, in HIV infec-
tion, HLA class I heterozygotes progress more slowly 
to AIDS than do homozygotes and that the viral load is 
significantly lower due to rare HLA class I alleles [27]. In 
relation to HTLV-1 infection, Goedert et al. showed that 
HLA class I diversity reduces the risk of ATLL presum-
ably by limiting the proliferation of HTLV-1 infected cells 
in vivo and therefore decreasing the possibilities of devel-
oping the disease [28].
The aim of this study was to identify HLA class I alleles 
associated to protection or susceptibility to disease and 
to analyze its possible association with proviral load in 
individuals infected with HTLV-1 living in Argentina.
Methods
Peripheral blood samples were obtained from a total of 
66 individuals, of which 52 presented HTLV-1 infec-
tion (9 ATLL, 22 HAM/TSP, 21 asymptomatic carri-
ers (AC)) and 14 non-infected individuals (NII). All of 
them attended our Institute seeking HTLV-1/2 diagnosis 
between 2003 and 2018.
The protocol was reviewed and approved by the Insti-
tutional Review Board as well as by the External Ethical 
Committee (NEXO AC IRB#0005349, protocol #1563). 
An informed consent was obtained from all individuals. 
The diagnosis of ATLL and HAM/TSP was performed in 
accordance with Tsukasaki and Osame criteria, respec-
tively [29]. Peripheral blood mononuclear cells (PBMCs) 
were isolated from EDTA-treated blood samples by a 
Ficoll-Hypaque density gradient (Ficoll Paque Plus, Sigma 
Aldrich, Saint Louis, USA) and DNA was extracted using 
a commercial kit (ADN PuriPrep-S kit, Inbio Highway, 
Tandil, Argentina). After serological screening, HTLV-1 
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infection was confirmed by an in-house nested poly-
merase chain reaction (n-PCR) as described elsewhere 
[30]. Absolute quantitation of PVL was performed by 
real-time SYBR Green PCR, using an ABI Prism 7500 
Prism System (Applied Biosystems, USA) as previously 
described [31, 32].
HLA class I characterization was performed by 
sequence based typing (SBT). HLA-A exons 2 and 3 were 
amplified together while HLA-B/C exons 2 and 3 were 
amplified separately, as described elsewhere [33].
Amplicons were sequenced using the Big Dye Ter-
minator sequencing kit (Applied Biosystems, USA) on 
a 3500xL Genetic Analyzer AB/HITACHI according to 
the manufacturer’s instructions.
For the calculation of allele frequencies, we counted 
each individual allele for each locus across all samples. 
In the cases where an individual resulted homozygous 
for a locus, this situation was equivalent to a count of 2 
for the corresponding allele.
For the analysis of homozygosis/ heterozygosis, 
we excluded from the total count those individuals 
whose haplotypes could not be typed, or were partially 
elucidated.
Table 1 Alleles previously associated with either protection or susceptibility to HTLV-1 associated diseases
Ac asymptomatic carriers, HAM/TSP HTLV-1 associated myelopathy/Tropical Spastic Paraparesis, ATLL Adult T cell leukemia/lymphoma, NII Non-infected Individuals, 
HLA Human leukocyte antigen
Country/Continent
(Reference)
N, Population Protective allele Detrimental allele
Africa [52] N = 45, Ac
N = 49, ATLL
N = 51, NII
– HLA-A*36
HLA-B*18
Brazil [18, 19] N = 71, HTLV-1 + 
N = 188, NII
HLA-A*02 (HAM) HLA-A*26 (ATLL)
N = 53, Ac
N = 55, HAM
HLA-A*02 –
Spain [14] N = 40, Ac
N = 20, HAM
– HLA-B*5401 absent
HLA-B*07
Iran [22, 24, 49] N = 74, Ac
N = 58, HAM
– HLA-B*5401
Iranian
N = 74, Ac
N = 58, HAM
Kagoshima
N = 184, Ac
N = 222, HAM
HLA-Cw*08 –
N = 20, HAM






Jamaica [17, 28] N = 45, Ac





N = 56, ATLL
N = 59, HAM
HLA-A*03 HLA-B*15
HLA-B*53
Japan [16, 20, 23, 53] N = 34, ATLL
N = 55, HAM





N = 175, NII
N = 152, Ac
N = 124, ATLL





N = 233, HAM




N = 201, Ac




Peru [21] N = 71, HAM
N = 94, Ac
HLA-A*02 –
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Data analysis was performed using the Kruskal–Wal-
lis non-parametric method; when two groups were com-
pared the  Chi2 test or Exact Fisher test, and one-way 
ANOVA were used. Epidat (version 4.2) and GraphPad 
Prism (version 6.03) software was applied and significant 
differences were defined as p < 0.05.
Results
We analyzed a total of in 66 individuals living in Argen-
tina of whom 16 were born in other South American 
countries such as Paraguay (6.1%, n = 4) and Peru (18.2%, 
n = 12). Among the 66 samples analyzed, there was no 
significant difference in biological sex (p = 0.410, Table 2) 
between asymptomatics and the group with HTLV-1 
associated pathologies. On the other hand, there was a 
significant difference in age (p = 0.002, mean age = 41.05, 
mean age NII = 32.27, mean age AC = 38.6, mean age 
HAM/TSP = 46.57, mean age ATLL = 44.33, Table  2) 
when analyzing the same groups. Table  2 presents the 
demographic characteristics of all studied individu-
als. None of the Argentine individuals reported being 
born nor have they been derived from endemic areas for 
HTLV-1 infection in the country.
Out of the 66 samples included in the study, a total of 
53 were typed for HLA-A (13 NII, 17 AC, 7 ATLL, 16 
HAM/TSP), 61 for HLA-B (14 NII, 19 AC, 7 ATLL, 21 
HAM/TSP) and 38 of them were analyzed for HLA-C 
(14 NII, 18 AC, 3 ATLL, 3 HAM/TSP). There were also a 
total of 14 samples for which only one of the alleles for a 
specific HLA I loci could be identified. Therefore, a total 
of 103 alleles could be typed for HLA-A, 112 for HLA-B 
and 74 for HLA-C.
Overall, A*02 (36.89%), B*35 (25.00%) and C*07 
(33.78%) were the most frequent in the population stud-
ied. Tables 3, 4 and 5 shows the frequencies of individual 
alleles in all the studied individuals.
In relation to HLA-A, the alleles A*23, A*24, A*32 and 
A*68 were observed among ATLL patients, but not in 
HAM/TSP, while the opposite case was found for A*11 
and A*29 in HAM/TSP patients but not ATLL. There was 
a significant difference in the frequency of HLA-A*02 
between asymptomatic carriers and those with ATLL 
(p = 0.031) (Table  3, Fig.  2). Allele A*01 was only found 
among NII; A*25 and A*26, among AC; A*11, among 
HAM/TSP patients; and A*23 and A*32 among ATLL 
patients.
For HLA-B, the alleles HLA-B*27 and B*40 were 
only found in NII; B*48 and B*53, only in AC; B*18, in 
ATLL; and B*13, B*15, B*41, B*49 and B*55, in HAM/
TSP individuals. Nevertheless, these alleles were too 
rare to draw any conclusions from these findings. The 
allele B*35 was significantly more frequent among the 
patients with HAM/TSP compared to asymptomatic 
carriers (p < 0,001) (Table 4, Fig. 2).
For the 38 HLA-C samples, the alleles C*01 and C*31 
were only found in NII, while the alleles C*05, C*06, 
C*16 and C*18 were exclusive for asymptomatic car-
riers. There were not any ATLL- or HAM-exclusive 
alleles. Overall, patients that had developed either one 
of the associated pathologies exhibited a rather lim-
ited arrange of alleles: only C*03, C*07 and C*15 were 
identified in our analysis. Out of the 3 pathology cases 
(1 HAM/TSP and 2 ATLL) that presented C*07, all of 
them were homozygotes for that loci and none dis-
played the allele A*02. In the AC group, 4 individuals 
presented C*07 (3 in homocigosis), and one individual 
was homozygous for A*02 (Fig. 1c, Table 5, Fig. 2). The 
allele HLA-C*07 was significantly higher among ATLL 
individuals (p = 0.017) compared to AC, but not among 
HAM/TSP patients (p = 0.466).
We repeated the analysis taking in consideration 
the Argentine individuals only (n = 50), the results 
showed differences in HLA-A*02, being significantly 
more frequent in AC than in ATLL (p = 0.025); and in 
HLA-C*07 which did not exhibit any difference among 
the studied groups. HLA-B*35 was not found in AC, 
whereas it was present in 12 out of 33 alleles for HAM/
TSP and 3 out of 13 for ATLL.
The mean PVL in asymptomatic carriers was 2.78 
per 100 PBMCs, and 10.44 in individuals with HTLV-1 
associated pathologies (16.36 for ATLL and 8.56 for 
HAM/TSP patients). PVL of patients with HTLV-1 
associated pathologies was significantly higher than 
that of asymptomatic carriers (p = 0.008, Tables  6, 
7 and 8) while there were no differences between the 
mean PVL of ATLL and HAM/TSP patients (p = 0.165, 
Tables  6, 7 and 8). Table  6, 7 and 8 presents the val-
ues of PVL classified per HLA-A, HLA-B and HLA-C 
alleles. No significant differences were observed for 
HLA-A, B and C when comparing the PVL among all 
the alleles of each loci by one-way ANOVA.
Most of the ATLL and HAM/TSP patients were 
homozygous for HLA-A (20/21) locus, in contrast to 
the HLA-B locus (4/21). Regarding heterozygosity, 
for the HLA-A locus there was a significant difference 
when comparing asymptomatics versus individuals 
with pathologies, heterozygosity being more frequent 
among asymptomatics (p = 0.038, Table  9). Neverthe-
less, all of the individuals with ATLL were heterozygous 
for HLA-B.
We found all of the ATLL and HAM patients that 
could be typed for HLA-C to be homozygous for 
this gene and all of the asymptomatic carriers to be 
homozygous for HLA-B (Table 9).
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Table 2 Demographic characteristics of the studied population
Code Population City/ Country of derivation Birthplace Biological sex Age (years) PVL
132,253 NII Buenos Aires Province Buenos Aires Province M 31 NA
132,254 HAM Buenos Aires Province Buenos Aires Province M 50 1.35
153,302 AC Buenos Aires City Buenos Aires City F 47 ND
154,545 NII Buenos Aires City Buenos Aires City F 22 NA
201,437 AC Buenos Aires City Buenos Aires Province M 31 0.39
203,568 AC Buenos Aires City Perú F 36 2.91
203,835 AC Buenos Aires City Buenos Aires Province M 18 0,68
325,784 NII Buenos Aires Province Peru F 36 NA
327,362 AC Buenos Aires Province Buenos Aires Province M 61 5.3
327,557 AC Buenos Aires Province Buenos Aires Province F 42 11.83
2,013,082 NII Buenos Aires Province Peru F 41 NA
2,013,100 HAM Buenos Aires City Buenos Aires Province M 49 4.03
2,013,102 AC Buenos Aires City Buenos Aires Province F 36 0.29
2,014,059 ATLL Buenos Aires City Entre Ríos F 62 ND
2,014,090 NII Buenos Aires City Buenos Aires City F 38 NA
2,014,101 AC Buenos Aires City Buenos Aires City M 32 0.58
2,014,102 AC Buenos Aires City Paraguay M 56 1.29
2,014,150 AC Buenos Aires Province Peru M 34 4.61
2,014,151 = 2,016,111 HAM Buenos Aires Province Peru F 61 12.86
2,014,160 AC Buenos Aires City Buenos Aires City F NA 0,57
2,014,161 NII Buenos Aires City Peru M NA NA
2,015,014 AC Buenos Aires City Paraguay M 34 1.12
2,015,024 AC Buenos Aires City Peru F 39 0,09
2,015,025 AC Buenos Aires City Peru M 43 2.51
2,015,038 NII Buenos Aires City Paraguay F 38 NA
2,015,059 NII Santa Fe Santa Fe F 23 NA
2,015,062 NII Santa Fe Santa Fe M 20 NA
2,015,074 = 2,017,009 AC Buenos Aires Province Peru F 39 10.77
2,015,082 NII Buenos Aires City Buenos Aires Province F 49 NA
2,015,090 AC Buenos Aires City Paraguay F 27 0.79
2,015,106 HAM Tucumán Perú F 41 2.00
2,015,107 ATLL Buenos Aires City Buenos Aires Province M 18 9.87
2,015,116 NII Buenos Aires City Misiones M 30 NA
2,016,001 NII Buenos Aires City Buenos Aires City F 27 NA
2,016,002 AC Buenos Aires City Buenos Aires City M 28 0.92
2,016,010 HAM Santa Fe Santa Fe F 45 10.3
2,016,049 AC Buenos Aires City Peru F 47 0.19
2,016,050 AC Buenos Aires City Peru M 52 1.46
2,016,065 AC Santa Fe Santa Fe M 48 9.24
2,016,066 AC Santa Fe Santa Fe M 22 0.11
20,110,055 = 20,110,063 ATLL Buenos Aires City Tucumán F 66 40.2
20,110,057 NII Buenos Aires City Tucumán F NA NA
20,110,059 NII Buenos Aires City Tucumán M NA NA
44,971 HAM Buenos Aires City NA F 25 3.12
45,674 HAM NA NA F 67 1.67
46,793 HAM Buenos Aires Province NA NA NA ND
49,067 HAM NA NA M 55 15.53
138,398 HAM NA NA F 56 29.54
146,570 HAM Buenos Aires Province NA F 51 4.78
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Discussion
It has been proposed that the HTLVs have arisen as a 
consequence of inter-species transmissions that took 
place millions of years ago in Africa and that HTLV-1 
was introduced in America during the multiple pre-
Columbian Mongoloid migrations over the Bering Strait, 
and in the post-Columbian era from Japan and with the 
slave trade from Africa. Therefore, the different migra-
tion waves of infected populations resulted in an ethnic/
geographical restriction in the American continent for 
HTLV-1 and 2. Moreover, Lou et  al. described certain 
polymorphisms as possibly associated to susceptibil-
ity for HTLV-1 infection for ethnically related popula-
tions of Russia (HLA-A*02, A*24) and Japan (HLA-A*24 
Table 2 (continued)
Code Population City/ Country of derivation Birthplace Biological sex Age (years) PVL
170,313 ATLL Buenos Aires City NA F 29 ND
174,908 HAM Buenos Aires City NA M 19 0.12
180,405 HAM Buenos Aires City NA F 71 10.45
192,816 HAM Buenos Aires City NA F 37 ND
195,086 ATLL Buenos Aires City NA F 48 1.30
198,544 ATLL Buenos Aires City NA F 67 12.49
209,803 HAM Buenos Aires City NA F 27 3.12
228,185 ATLL Buenos Aires City NA M 53 33.98
244,886 ATLL Santa Fe NA M 31 ND
248,684 HAM Buenos Aires City NA M 65 5.39
255,404 HAM Buenos Aires City NA M 31 ND
20,110,028 HAM Buenos Aires City NA F 52 8.57
2,012,028 HAM Buenos Aires City NA M 52 35.10
2,012,135 ATLL Buenos Aires City NA M 25 0,34
20,110,001 HAM Buenos Aires City NA F 43 0.71
2,014,057 HAM Buenos Aires City NA M 41 13.09
2,014,063 HAM Tucumán NA F 40 1.01
NII Non-infected Individual, AC Asymptomatic Carrier, HAM HTLV-1 associated myelopathy, ATLL adult T cell leukemia/lymphoma, F Female, M Male, PVL proviral load, 
NA not available, ND not determined
Table 3 Number and frequency of every HLA-A allele found in our population for each group
NII non infected individual, AC Asymptomatic Carrier, ATLL Adult T cell leukemia/lymphoma, HAM HTLV-1- associated myelopathy
Allele Population Overall Allele frequency
NII AC ATLL HAM
HLA-A*01 4 0 0 0 4 0.039
HLA-A*02 7 17 2 12 38 0.369
HLA-A*03 2 1 0 0 3 0.029
HLA-A*11 0 0 0 2 2 0.019
HLA-A*23 0 0 1 0 1 0.010
HLA-A*24 4 4 1 0 9 0.087
HLA-A*25 0 1 0 0 1 0.010
HLA-A*26 0 1 0 0 1 0.010
HLA-A*29 2 0 0 4 6 0.058
HLA-A*31 1 5 4 7 17 0.165
HLA-A*32 0 0 2 0 2 0.019
HLA-A*33 1 3 1 6 11 0.107
HLA-A*68 3 1 2 0 6 0.058
HLA-A*69 1 1 0 0 2 0.019
Overall 25 34 13 31 103 1
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and A*26) [15, 34]. In the general population of Argen-
tina the reported frequencies of A*02, A*24 and A*26 
were 24.95%, 11.25% and 4.02%, respectively [35]. In the 
studied population (Table  3, 4 and 5) there was a high 
frequency of allele A*02 (36.89%), and following the ten-
dency of the data reported in the general population, the 
frequencies of A*24 (8.74%), A*26 (0.97%) were lower. 
When comparing the group of NII against HTLV-1+ 
individuals, there were no significant differences between 
them, therefore a bigger sample size could determine if 
there is an association regarding their frequency and 
HTLV-1 infection status. In the case of HLA-B and -C, 
Table 4 Number and frequency of every HLA-B allele found in our population for each group
NII non infected individual, AC Asymptomatic Carrier, ATLL Adult T cell leukemia/lymphoma, HAM HTLV-1- associated myelopathy
B Population Overall Allele frequency
NII AC ATLL HAM
HLA-B*07 1 2 0 0 3 0.027
HLA-B*08 2 2 0 3 7 0.063
HLA-B*13 0 0 0 1 1 0.009
HLA-B*14 2 2 1 2 7 0.063
HLA-B*15 0 0 0 2 2 0.018
HLA-B*18 0 0 2 0 2 0.018
HLA-B*27 2 0 0 0 2 0.018
HLA-B*35 8 2 3 15 28 0.25
HLA-B*38 4 4 0 0 8 0.071
HLA-B*39 5 4 4 2 15 0.134
HLA-B*40 2 0 0 0 2 0.018
HLA-B*41 0 0 0 1 1 0.009
HLA-B*44 0 2 1 1 4 0.036
HLA-B*48 0 8 0 0 8 0.071
HLA-B*49 0 0 0 1 1 0.009
HLA-B*51 0 3 2 5 10 0.089
HLA-B*52 0 2 0 2 4 0.036
HLA-B*53 0 6 0 0 6 0.054
HLA-B*55 0 0 0 1 1 0.009
Overall 26 37 13 36 112 1
Table 5 Number and frequency of every HLA-C allele found in our population for each group
NII non infected individual, AC Asymptomatic Carrier, ATLL Adult T cell leukemia/lymphoma, HAM HTLV-1- associated myelopathy
Allele Population Overall Allele frequency
NII AC ATLL HAM
HLA-C*01 1 0 0 0 1 0.014
HLA-C*03 10 4 0 4 18 0.243
HLA-C*04 1 6 0 0 7 0.095
HLA-C*05 0 2 0 0 2 0.027
HLA-C*06 0 2 0 0 2 0.027
HLA-C*07 12 7 4 2 25 0.338
HLA-C*12 2 1 0 0 3 0.041
HLA-C*15 0 8 2 0 10 0.135
HLA-C*16 0 3 0 0 3 0.041
HLA-C*18 0 2 0 0 2 0.027
HLA-C*31 1 0 0 0 1 0.014
Overall 27 35 6 6 74 1
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the most common alleles in Argentina are B*35 (14.6%), 
B*44 (11.4%) and B*51 (7.9%), and C*07 (24.6%), C*04 
(16.6%) and C*03 (10.4%) (35). Our own population 
largely matched these data, except for the cases of alleles 
B*44 and C*04, which were relatively uncommon (3.6% 
and 9.5%, respectively). B*44 was only present in HTLV-1 
individuals while for C*04 no significant differences 
were found when comparing non-infected individu-
als vs HTLV-1 patients (p = 0.097). Instead, alleles B*39 
(13.4%), C*03 (24.3%) and C*15 (13.5%) were among the 
top found. It should be noted that all the alleles are pre-
sent in a lower proportion in the general population than 
in our own due to the fact that there was a smaller variety 
of alleles found in the latter, which translates in a bigger 
proportion of the total distribution for each of them.
Regarding, the thirteen Peruvian and the four Para-
guayan individuals sampled, the allele frequencies 
matched the reported prevalence in these populations 
[36, 37]. The most frequent alleles for HLA-A in the gen-
eral population in Peru were A*02, A*24 and A*68, in 
decreasing order, which correlated with our own find-
ings. The same happened for HLA-B (most frequent 
HLA-B*35), and HLA-C, the most common allele being 
Cw*04. In our own population, we found 7 copies of said 
allele, 4 of which corresponded to Peruvian individuals. 
When it came to the four Paraguayan individuals tested, 
the most common alleles were HLA-A*02 and HLA-
B*35, the same as for the general population in that coun-
try, although for the case of the indigenous Guaraní, the 
most common HLA-B alleles were HLA-B*15 and B*40. 
Nevertheless, when repeating the analysis taking in con-
sideration the Argentine individuals only (n = 50), for 
HLA-A*02 the difference between AC and ATLL is still 
conserved (p = 0.025) in concordance to reports that 
associated this allele to protection against developing 
HTLV-1 associated pathologies. For HLA-B*35, we found 
no AC individuals that carried the allele, which indicates 
an even stronger correlation between this allele and sus-
ceptibility to HAM/TSP. HLA-C*07, nonetheless, was no 
longer correlated to susceptibility to ATLL when exclud-
ing non-Argentine individuals.
Regarding the pathologies associated to HTLV-1 
infection, it is known that most individuals remain 
asymptomatic throughout their lives. ATLL and HAM/
Fig. 1 Demographic characteristics of the studied population. a Distribution by gender. b Distribution by age range. c Distribution by region of 
derivation. d Distribution by province/country of birth
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Fig. 2 Allele distribution in the different subgroups. a Distribution 
of HLA-A in the 4 subgroups: non-infected individuals (NII), HTLV-1 
asymptomatic carriers (AC), patients with Adult T-cell leukemia/ 
lymphoma (ATLL) and patients with HTLV-1 associated myelopathy/ 
Tropical Spastic Paraparesis (HAM/TSP). b Distribution of HLA-B in the 
4 subgroups: NII, AC, ATLL and HAM/TSP. c Distribution of HLA-C in 
the 4 subgroups: NII, AC, ATLL and HAM/TSP
◂
TSP patients are more frequent in areas of high ende-
micity and they represent a small percentage of the 
infected population (up to 5%).
The reasons behind the development of pathologies 
during adulthood and their association to host genetic 
factors are still unclear even though many hypotheses 
have been proposed. HLA class I genes may have an 
effect on the progression towards ATLL and HAM/TSP 
due to its critical role in antigen presentation [15]. Var-
ious alleles have been described as either protective or 
susceptible for the development of ATLL or HAM/TSP. 
In Jamaica, Japan and Brazil the allele HLA-A*02 has 
been described as protective both for ATLL and HAM/
TSP, in accordance with other studies which reported 
finding it significantly more frequent in asymptomatic 
carriers [15, 19, 34]. In our population, A*02 was sig-
nificantly rarer in ATLL patients when compared to 
HTLV-1+ asymptomatic carriers, suggesting as well 
a protective role for this allele in this group. This pro-
tective role could not be confirmed for HAM/TSP 
patients in this study. The allele HLA-A*03, previously 
Table 6 Proviral load for  each HLA-A allele and  clinical 
status
AC asymptomatics carriers, HAM HTLV-1 associated myelopathy, ATLL Adult T 
cell leukemia/lymphoma, NII Non-infected Individuals, HLA Human leukocyte 
antigen, PVL proviral load
* Only the PVL of one allele was available, **Mean PVL of two alleles
Allele Population Mean PVL
AC ATLL HAM
HLA-A*02 1.42 12.49* 4.35 3.13
HLA-A*03 4.61* – – 4.61
HLA-A*11 – – 4.03* 4.03
HLA-A*23 – 0.34* – 0.34
HLA-A*24 6.64 0.34* – 4.54
HLA-A*25 1.29* – – 1.29
HLA-A*26 1.29* – – 1.29
HLA-A*29 – – 9.32** 9.32
HLA-A*31 1.29 33.98 15.1 12.28
HLA-A*32 – 9.82* – 9.82
HLA-A*33 1.85** 40.2* 11.12 12.88
HLA-A*68 4.61* 1.3* – 2.95
HLA-A*69 ND – – ND
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described as protective in Jamaica, was only found in 
asymptomatic patients and healthy donors in the stud-
ied population and with a low frequency.
We did not found any associations linking HLA-A*26 
to either protection or susceptibility to ATLL, although 
it should be pointed out that this allele is not frequently 
found in the Argentine population (4.02%) [35] and it was 
even rarer in our population, having been found only in 
one individual.
In the case of HLA-B allele distribution, B*35 was 
found to be significantly more frequent in patients with 
HAM/TSP than in asymptomatics, which could point to 
a possible association of this allele to the development of 
diseases. Although B*35 has been previously linked to 
progression to disease, viral load, heterosexual transmis-
sion and mother to child transmission in HIV-1 infected 
individuals and to disease progression in HBV, this is the 
first report about this allele in relation to HTLV-1 infec-
tion [38–40].
Regarding HLA-C, our analysis yielded similar results 
with previous studies in Brazil and Japan, which reported 
a correlation between HLA-C*07 and progression to dis-
ease, even though in our case it was associated to ATLL 
(p = 0.017) and not to HAM/TSP (p = 0.466) [16, 25]. 
None of the individuals with pathologies presented HLA-
C*07 and HLA-A*02 concomitantly, and only one out of 
four AC had them both; therefore, we could not find the 
protective effect of HLA-A*02 from HLA-C*07.
Another aspect to be considered is that all of the alleles 
found solely in one group had a very low frequency; many 
of them were actually identified that one time (Table 2). 
They were also very rare alleles for the general Argentine 
population [35]. Thus, it is not possible to draw any con-
clusions regarding these findings. The only exceptions 
were HLA-B*48 and HLA-B*53, which had a frequency 
of 7.14% (8/112) and 5.36% (6/112) (Table 4), respectively 
and were found solely in AC.
Many biomarkers have been proposed as prognostic 
for development of either ATLL (PD-1/PD-L1, absence 
of CD7 in  CD4+ T cells [41–43] or HAM (CXCL10, 
CXCL9, neopterin and HTLV-1 antibody titers in CSF, 
and gender [44–46], although the most studied is PVL.
To this day, the therapies for HTLV-1 associated 
pathologies seek to reduce the proviral load. In the last 
decade, a real time quantitative PCR (qPCR) has been 
Table 7 Proviral load for  each HLA-B allele and  clinical 
status
AC asymptomatics carriers, HAM HTLV-1 associated myelopathy, ATLL Adult T 
cell leukemia/lymphoma, NII Non-infected Individuals, HLA Human leukocyte 
antigen, PVL proviral load
* Only the PVL of one allele was available, **Mean PVL of two alleles
Allele Population Mean PVL
AC ATLL HAM
HLA-B*07 11.83* – – 11.83
HLA-B*08 0.39* – 15.12 10.21
HLA-B*13 – – 35.1* 35.1
HLA-B*14 5.3* 1.3* 3.58** 3.44
HLA-B*15 – – 3.07** 3.07
HLA-B*18 – 0.82** – 0.81
HLA-B*35 – 5.1** 6.44 6.12
HLA-B*38 2.1** – – 2.1
HLA-B*39 0.24 18.78 7.84 10.36
HLA-B*41 – – ND ND
HLA-B*44 0.58* 33.98* 29.54* 21.36
HLA-B*48 1.24 – – 1.24
HLA-B*49 – – 35.1* 35.1
HLA-B*51 0.74 12.49* 3.7 4.11
HLA-B*52 0.57* – 9.32** 6.41
HLA-B*53 3.42 – – 3.42
HLA-B*55 – – 4.03* 4.03
Table 8 Proviral load for  each HLA-C allele and  clinical 
status
AC asymptomatics carriers, HAM HTLV-1 associated myelopathy, ATLL Adult T 
cell leukemia/lymphoma, NII Non-infected Individuals, HLA Human leukocyte 
antigen, PVL proviral load
* Only the PVL of one allele was available, **Mean PVL of two alleles
Allele Population Mean PVL
AC ATLL HAM
HLA-C*03 2.7** – 1.675** 2.19
HLA-C*04 0.47 – – 0.47
HLA-C*05 0.11* – – 0.11
HLA-C*06 0.92* – – 0.92
HLA-C*07 1.69 40.2* 4.03* 8.5
HLA-C*12 0.58* – – 0.58
HLA-C*15 1.89 9.87* – 3.49
HLA-C*16 2.94** – – 2.94
HLA-C*18 0.39* – – 0.39
Table 9 Number of homozygous patients for each gene
Population HLA-A HLA-B HLA-C
NII 10/12 11/12 11/13
AC 12/17 18/18 15/17
ATLL 5/6 0/6 3/3
HAM 15/15 4/15 3/3
Overall 42/50 33/51 32/36
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implemented for the quantification of proviral load (PVL) 
of HTLV-1/2 from cells of infected patients. Its determi-
nation is used as an indicator of the course of infection 
in asymptomatic carries in order to evaluate their predis-
position to the development of pathology and to monitor 
treatment progression in ATLL and HAM patients [47]. 
It has been reported that, although the PVL has been 
suggested to be directly related to the severity of the dis-
ease, the values among infected individuals often vary 
significantly [48]. This corresponds with the dispersion 
of the values observed in this study. Previously reported 
values indicate that in asymptomatic carriers, the mean 
proviral load is 0.1–1 copy/100 PBMCs, while in patients 
with HAM/TSP is 5–10/100 PBMCs, exceeding some-
times 30 copies [48]. Despite these differences observed 
in the PVL values and the technique used, all the reports 
conclude that there is a significant difference among 
asymptomatics and patients with pathologies as observed 
in our studied population. These results also indicate that 
there is a correlation towards disease progression [33].
Some studies have proposed that HLA allelic variants 
could determine the PVL levels of HTLV-1 infected indi-
viduals [14, 49]. Nonetheless, we couldn’t find any signifi-
cant differences in the PVL of any allele to support these 
previous claims (Tables 6, 7 and 8).
It has been proposed that heterozygosis on HLA con-
fers advantages on disease progression in AIDS, reveal-
ing a greater variety of the immune response [50, 51]. 
In accordance to this, heterozygosis for HLA-A was sig-
nificantly more frequent among asymptomatics when 
compared to individuals with pathologies. However, the 
opposite was true for HLA-B, for which homozygosis was 
more frequent in asymptomatic carriers than in patients 
with pathologies (Table 9).
In conclusion, several HLA alleles identified in our 
study were associated with disease progression. Our 
results add more evidence to the protective effect of 
HLA-A*02 allele on progression to ATLL, and draws 
attention to HLA-B*35 as a new allele to be considered 
in relation to susceptibility to HAM/TSP, and also HLA-
C*07 in relation to progression to ATLL.
To this day, however, no allele or allele pattern has been 
identified to be exclusive to either asymptomatic indi-
viduals or those who develop pathologies, and to thus 
be of use when it comes to providing a predictive diag-
nosis. Were an allele like this to be found, in line with 
the rapidly evolving field of precision medicine, it would 
mean the possibility to conduct a closer follow up of each 
asymptomatic HTLV-1+ carrier, for those patients that 
choose to learn the impact of their genetic background 
on the infection by HTLV-1.
Conclusions
We have found HLA-A*02, HLA-B*35 and HLA-C*07 
to be associated to protection from ATLL (HLA-A*02) 
and susceptibility to HAM/TSP (HLA-B*35) or to ATLL 
(HLA-C*07), respectively. Whereas HLA-A*02 protec-
tion from ATLL has already been extensively described 
in other regions of the world, this is the first report that 
links HLA-B*35 and an increased susceptibility to HAM/
TSP. As for HLA-C*07 it has previously been associated 
to susceptibility to HAM/TSP in other countries but in 
our population it has been linked to ATLL.
These alleles could be of relevance, among other mark-
ers, to determine a model for disease development prog-
nosis and helping the generation of a vaccine for use  in 
different geographical areas around the world.
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